AI-powered regulatory document generation is moving from experimental to measurable. Recent vendor reports suggest draft CSR generation time can drop by up to 90%, and industry surveys show organizations with 18+ months of AI experience report 72.9% seeing shorter trial timelines. The financial stakes are substantial: a single day of Phase II/III trial delay costs approximately $40,000 in direct costs plus $500,000 in lost prescription sales, according to Tufts CSDD. Protocol amendments, which affect 60% of protocols at an average cost of $1.04 million each, represent another major cost driver that better initial drafting could reduce.
The ROI varies by document type. CSRs offer the highest per-document return because they're data-intensive and typically require weeks of back-and-forth revisions. Protocols offer preventive value by reducing amendment probability. For site staff, this means faster startup timelines as ICFs and protocols arrive cleaner and require fewer IRB query cycles.
Important context: most performance figures come from vendor reports rather than independent validation. The actual ROI depends on whether documentation sits on your critical path. If you're waiting on manufacturing inspections or regulatory review queues, faster drafting won't move your submission date. Sites evaluating AI tools should request evidence from compara

